Workflow
通化东宝(600867) - 2025 Q2 - 季度业绩预告(更正)
THDBTHDB(SH:600867)2025-07-14 07:50

Current Period Performance Forecast (2025 Semi-Annual) The company anticipates a return to profitability in the first half of 2025, with net profit attributable to shareholders estimated at approximately RMB 217.35 million and non-recurring net profit at approximately RMB 220.15 million, based on unaudited preliminary figures Estimated Performance (2025 Semi-Annual) | Metric | Estimated Amount (RMB) | Notes | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Approx. 217.35 million | Return to Profitability | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | Approx. 220.15 million | - | - This performance forecast has not been audited by a certified public accountant5 Prior Period Operating Performance (2024 Semi-Annual) In the corresponding period of 2024, the company reported a net loss attributable to shareholders of RMB 230.49 million, a non-recurring net loss of RMB 13.30 million, and earnings per share of RMB -0.12 Prior Period Operating Performance (2024 Semi-Annual) | Metric | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | -230.49 million | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | -13.30 million | | Earnings Per Share | -0.12 | Primary Reasons for Current Period Profit Forecast The primary driver for the return to profitability in the first half of 2025 is the increased revenue from the company's insulin product series, attributed to significant growth in domestic sales of insulin analogs and notable increases in export revenue from successful internationalization efforts - The main reason for the return to profitability is the growth in revenue from the company's insulin product series, driving profit growth9 - In the domestic market, significant sales growth of insulin analog products led to a substantial increase in domestic sales revenue9 - In the international market, the company's internationalization strategy achieved remarkable results, leading to a significant increase in export revenue9 Risk Warning and Other Disclosures The company states there are no significant uncertainties affecting the accuracy of this performance forecast, but emphasizes that the disclosed data are preliminary financial estimates, unaudited, and subject to the final 2025 semi-annual report - The company confirms there are no uncertain factors that would significantly impact the accuracy of this performance forecast10 - This performance forecast is based on preliminary calculations by the company's finance department and has not been audited by a certified public accountant; the final data will be subject to the official semi-annual report for 20251011